Detalles de la búsqueda
1.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs;
41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
2.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res;
53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216
3.
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
Hepatol Res;
53(11): 1059-1072, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537735
4.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat;
29(7): 551-558, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35548866
5.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Invest New Drugs;
40(6): 1290-1297, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152108
6.
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Clin Infect Dis;
73(9): e3349-e3354, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33544129
7.
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
J Med Virol;
93(11): 6247-6256, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34170517
8.
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Hepatol Res;
49(3): 264-270, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171740
9.
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Hepatol Res;
49(10): 1114-1120, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31077527
10.
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis.
Hepatol Res;
48(9): 746-756, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29480939
11.
Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease.
J Gastroenterol Hepatol;
33(1): 283-290, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28497593
12.
Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group.
Hepatol Res;
46(4): 251-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25753220
13.
Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies.
Hepatol Res;
46(10): 992-1001, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26670363
14.
Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy.
Hepatol Res;
45(8): 872-9, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25244601
15.
Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.
Hepatol Res;
44(1): 83-91, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23530991
16.
Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice.
Hepatol Res;
44(8): 920-34, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23834389
17.
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
JGH Open;
8(4): e13068, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38681824
18.
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.
JGH Open;
7(6): 424-430, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37359109
19.
Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection.
JGH Open;
6(5): 344-352, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35601120
20.
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Cancers (Basel);
14(12)2022 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35740647